Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI?

Nature Clinical Practice Cardiovascular Medicine volume 5, pages 252–253 (2008)Cite this article

boxed-textWiviott SD et al. for the TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001–2015

Background

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Yusuf S et al. for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494–502

    Article  CAS  Google Scholar 

  2. Sabatine MS et al. for the CLARITY-TIMI 28 Investigators (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352: 1179–1189

    Article  CAS  Google Scholar 

  3. Bhatt DL (2006) Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction? Nat Clin Pract Cardiovasc Med 3: 182–183

    Article  Google Scholar 

  4. Bhatt DL and Topol EJ (2003) Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2: 15–28

    Article  CAS  Google Scholar 

  5. Bhatt DL (2007) Intensifying platelet inhibition—navigating between Scylla and Charybdis. N Engl J Med 357: 2078–2081

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Cardiovascular Medicine, Cleveland Clinic, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA bhattd@ccf.org

Authors and Affiliations

  1. DL Bhatt is an Interventional Cardiologist, Associate Director of the Cardiovascular Coordinating Center, and Associate Professor of Medicine at the Cleveland Clinic in Cleveland, OH, USA.,

    Deepak L Bhatt

Authors
  1. Deepak L Bhatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

DL Bhatt has received research funding (directly to the Cleveland Clinic) from Bristol-Myers Squibb, Eisai, Ethicon, Heartscape Technologies, Sanofi-Aventis, and The Medicines Company. He has received payments for Speaker's Bureau appointments from Bristol-Myers Squibb, Sanofi-Aventis, and The Medicines Company. He has received honoraria from AstraZeneca, Bristol-Myers Squibb, Centocor, Eisai, Eli Lilly, GlaxoSmithKline, Millennium Pharmaceuticals, ParinGenix, PDL BioPharma, Sanofi-Aventis, Schering Plough, The Medicines Company, and TNS Healthcare. He has also acted as a Consultant or Advisory Board member for Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Cardax Pharmaceuticals, Centocor, Cogentus Pharmaceuticals, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Medtronic, Millennium Pharmaceuticals, Molecular Insight Pharmaceuticals, Ortho-McNeil Pharmaceutical, Otsuka, ParinGenix, PDL BioPharma, Philips Medical, Portola Pharmaceuticals, Sanofi-Aventis, Schering Plough, Scios, The Medicines Company, TNS Healthcare, and Vertex Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bhatt, D. Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI?. Nat Rev Cardiol 5, 252–253 (2008). https://doi.org/10.1038/ncpcardio1164

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio1164

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing